These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30479703)

  • 1. Non-profit drug research and development: the case study of Genethon.
    Jarosławski S; Toumi M
    J Mark Access Health Policy; 2019; 7(1):1545514. PubMed ID: 30479703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-profit Drug Research and Development at a Crossroads.
    Jarosławski S; Toumi M; Auquier P; Dussart C
    Pharm Res; 2018 Feb; 35(3):52. PubMed ID: 29417233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Private versus social incentives for pharmaceutical innovation.
    González P; Macho-Stadler I; Pérez-Castrillo D
    J Health Econ; 2016 Dec; 50():286-297. PubMed ID: 26944633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affordably priced new drugs for poor populations: Approaches for a global solution.
    Mossialos E; Dukes G
    Int J Risk Saf Med; 2001; 14(1):1-29. PubMed ID: 22388482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms' R&D Investment in China? An Event Study Approach.
    Hu Y; Chen S; Qiu F; Chen P; Chen S
    Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
    Han E; Kim TH; Jeung MJ; Lee EK
    Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Market power in the United States red meatpacking industry.
    Koontz SR
    Vet Clin North Am Food Anim Pract; 2003 Jul; 19(2):519-44. PubMed ID: 12951745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&D.
    Schulthess D; Gassull D; Maisel S
    Ther Innov Regul Sci; 2019 Nov; 53(6):746-751. PubMed ID: 31771361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework.
    Moreno SG; Epstein D
    J Mark Access Health Policy; 2019; 7(1):1583536. PubMed ID: 30956782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Use of Gene Therapy Orphan Drugs-Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society.
    Kerpel-Fronius S; Baroutsou V; Becker S; Carlesi R; Collia L; Franke-Bray B; Kleist P; Kurihara C; Laranjeira LF; Matsuyama K; Naseem S; Schenk J; Silva H
    Front Med (Lausanne); 2020; 7():608249. PubMed ID: 33425952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Way to Boost the Impact of Business on 2030 United Nations Sustainable Development Goals: Co-creation With Non-profits for Social Innovation.
    Díaz-Perdomo Y; Álvarez-González LI; Sanzo-Pérez MJ
    Front Psychol; 2021; 12():719907. PubMed ID: 34421771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical Overview of Pharmaceutical Industry Policies in Turkey from Various Perspectives.
    Oral M; Özçelikay G
    Turk J Pharm Sci; 2017 Dec; 14(3):264-273. PubMed ID: 32454623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social Non-profit Bioentrepreneurship: Current Status and Future Impact on Global Health.
    Sadeghi AH; Koldeweij C; Trujillo-de Santiago G; Tannazi M; Hosseinnia N; van Loosbroek O; Manbachi A; Taverne YJHJ; Bogers AJJC; Alvarez MM
    Front Public Health; 2021; 9():541191. PubMed ID: 34660499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
    Ledley FD; McCoy SS; Vaughan G; Cleary EG
    JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creative compliance in pharmaceutical markets: the case of profit controls.
    Bradley J; Vandoros S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):31-8. PubMed ID: 22280194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
    Yamakawa K
    Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ethics and economics of pharmaceutical pricing.
    Parker-Lue S; Santoro M; Koski G
    Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.